drugset / Trial / NCT00624910

Efficacy and Safety of a Collagen Bupivacaine Implant in Women Following Abdominal Hysterectomy

NCT00624910

Phase 2 Completed 54 enrolled Innocoll Premier Research · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether the CollaRx Bupivacaine implant is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 24 hours after abdominal hysterectomy surgery.

Timeline

Start
2007-12-27
Primary completion
2008-09-05
Completion
2008-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 150 mg Other

Indications

No indication recorded.